CoviRx: A User-Friendly Interface for Systematic Down-Selection of Repurposed Drug Candidates for COVID-19

Hardik A. Jain, Vinti Agarwal (), Chaarvi Bansal, Anupama Kumar, Faheem, Muzaffar-Ur-Rehman Mohammed, Sankaranarayanan Murugesan, Moana M. Simpson, Avinash V. Karpe, Rohitash Chandra, Christopher A. MacRaild, Ian K. Styles, Amanda L. Peterson, Matthew A. Cooper, Carl M. J. Kirkpatrick, Rohan M. Shah, Enzo A. Palombo, Natalie L. Trevaskis, Darren J. Creek and Seshadri S. Vasan ()
Additional contact information
Hardik A. Jain: Birla Institute of Technology and Science, Department of Electrical and Electronics Engineering, Pilani 333031, Rajasthan, India
Vinti Agarwal: Birla Institute of Technology and Science, Department of Computer Science and Information Systems, Pilani 333031, Rajasthan, India
Chaarvi Bansal: Birla Institute of Technology and Science, Department of Computer Science and Information Systems, Pilani 333031, Rajasthan, India
Anupama Kumar: Commonwealth Scientific and Industrial Research Organisation, Land and Water, Waite Campus, Urrbrae, SA 5064, Australia
Faheem: Birla Institute of Technology and Science, Department of Pharmacy, Pilani 333031, Rajasthan, India
Muzaffar-Ur-Rehman Mohammed: Birla Institute of Technology and Science, Department of Pharmacy, Pilani 333031, Rajasthan, India
Sankaranarayanan Murugesan: Birla Institute of Technology and Science, Department of Pharmacy, Pilani 333031, Rajasthan, India
Moana M. Simpson: Compounds Australia, Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111, Australia
Avinash V. Karpe: Department of Chemistry and Biotechnology, Swinburne University of Technology, Hawthorn, VIC 3122, Australia
Rohitash Chandra: School of Mathematics and Statistics, University of New South Wales, Sydney, NSW 1466, Australia
Christopher A. MacRaild: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3800, Australia
Ian K. Styles: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3800, Australia
Amanda L. Peterson: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3800, Australia
Matthew A. Cooper: Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
Carl M. J. Kirkpatrick: Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
Rohan M. Shah: Department of Chemistry and Biotechnology, Swinburne University of Technology, Hawthorn, VIC 3122, Australia
Enzo A. Palombo: Department of Chemistry and Biotechnology, Swinburne University of Technology, Hawthorn, VIC 3122, Australia
Natalie L. Trevaskis: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3800, Australia
Darren J. Creek: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3800, Australia
Seshadri S. Vasan: Commonwealth Scientific and Industrial Research Organisation, Australian Centre for Disease Preparedness, Geelong, VIC 3220, Australia

Data, 2022, vol. 7, issue 11, 1-19

Abstract: Although various vaccines are now commercially available, they have not been able to stop the spread of COVID-19 infection completely. An excellent strategy to get safe, effective, and affordable COVID-19 treatments quickly is to repurpose drugs that are already approved for other diseases. The process of developing an accurate and standardized drug repurposing dataset requires considerable resources and expertise due to numerous commercially available drugs that could be potentially used to address the SARS-CoV-2 infection. To address this bottleneck, we created the CoviRx.org platform. CoviRx is a user-friendly interface that allows analysis and filtering of large quantities of data, which is onerous to curate manually for COVID-19 drug repurposing. Through CoviRx, the curated data have been made open source to help combat the ongoing pandemic and encourage users to submit their findings on the drugs they have evaluated, in a uniform format that can be validated and checked for integrity by authenticated volunteers. This article discusses the various features of CoviRx, its design principles, and how its functionality is independent of the data it displays. Thus, in the future, this platform can be extended to include any other disease beyond COVID-19.

Keywords: COVID-19; drug fingerprints; drug repurposing; open-source dataset; search engine; web application development; web scraping (search for similar items in EconPapers)
JEL-codes: C8 C80 C81 C82 C83 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/2306-5729/7/11/164/pdf (application/pdf)
https://www.mdpi.com/2306-5729/7/11/164/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jdataj:v:7:y:2022:i:11:p:164-:d:976387

Access Statistics for this article

Data is currently edited by Ms. Cecilia Yang

More articles in Data from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().